Tag: 1994

Human herpesvirus-7 (HHV-7)

Abstract:

HHV-7 first isolated in 1990 from a healthy individual, is a ubiquitous agent. The second independent isolation of HHV-7 from a chronic fatigue syndrome patient was reported in 1992. The seroepidemiology of HHV-7 suggested that its prevalence rate in the U.S.A. population is > 85%; however, in Japan a low prevalence rate has been reported. HHV-7 can be more readily isolated from the saliva than HHV-6. The primary infection of HHV-7 appears later in life than HHV-6. No disease has been reported that is etiologically linked to HHV-7. HHV-7 is more closely related to HHV-6 and the human cytomegalovirus than other members of the human herpesvirus family.

 

Source: Ablashi DV, Berneman ZN, Kramarsky B, Asano Y, Choudhury S, Pearson GR. Human herpesvirus-7 (HHV-7). In Vivo. 1994 Jul-Aug;8(4):549-54. http://www.ncbi.nlm.nih.gov/pubmed/7893982

 

Clinical correlates of infection with human herpesvirus-6

Abstract:

Human herpesvirus-6 is a lymphotropic virus which infects susceptible individuals during the first year of life and usually causes life-long latency. In a variable percentage primary infections are followed by a short acute disease, exanthema subitum. Older individuals may suffer from infectious mononucleosis-like illnesses or from Kikuchi-Fujimoto’s disease. In addition, there is a fairly wide spectrum of lymphoid and hematopoietic diseases or autoimmune disorders, which are associated with elevated titers of HHV-6 antibody, and from which replicating virus may be isolated. Such diseases include atypical polyclonal lymphoproliferation, Hodgkin’s disease, chronic fatigue syndrome and systemic lupus erythematosus. The present article reviews the current knowledge of such associations.

 

Source: Krueger GR, Klueppelberg U, Hoffmann A, Ablashi DV. Clinical correlates of infection with human herpesvirus-6. In Vivo. 1994 Jul-Aug;8(4):457-85. http://www.ncbi.nlm.nih.gov/pubmed/7893974

 

Neuropsychology and psychology of MCS

Abstract:

Neurological symptoms are frequently reported by patients with multiple chemical sensitivities (MCS). Methods to compare the psychiatric, personality, and neuropsychological function of patients with MCS, chronic fatigue syndrome (CFS), and normal controls are described. Increased rates of Axis I psychiatric diagnoses are observed in the literature for MCS and CFS subjects relative to controls.

Findings on the MMPI-2 and the Toronto Alexithymia Scale reveal profiles consistent with the tendency to report somatic rather than emotional symptoms in response to stress. However, many of the reported somatic symptoms also coincide with those found in neurologic disorders. The overall neuropsychological profile for MCS subjects does not reflect cognitive impairment.

Relative to normal controls, the only difference in neuropsychological performance observed is reduced recognition of nontarget designs on a visual memory task. More fruitful areas for future psychological research will include measurement of the interaction between behavioral response styles and attentional processes in cognition, as well as observations under controlled challenge conditions.

 

Source: Fiedler N, Kipen H, Deluca J, Kelly-McNeil K, Natelson B. Neuropsychology and psychology of MCS. Toxicol Ind Health. 1994 Jul-Oct;10(4-5):545-54. http://www.ncbi.nlm.nih.gov/pubmed/7778113

 

Neuropsychiatric status of patients with chronic fatigue syndrome: an overview

Abstract:

Chronic fatigue syndrome (CFS) is an illness that results in debilitating fatigue as well as rheumatological, infectious, and neuropsychiatric symptoms. The present paper is a brief overview of the neuropsychological and psychiatric research on CFS. Studies from our laboratory contrasting CFS with patients with multiple sclerosis, depression, and healthy controls are detailed. Our hypothesis of neuropsychological impairments in CFS is discussed.

 

Source: Deluca J, Johnson SK, Natelson BH. Neuropsychiatric status of patients with chronic fatigue syndrome: an overview. Toxicol Ind Health. 1994 Jul-Oct;10(4-5):513-22. http://www.ncbi.nlm.nih.gov/pubmed/7778111

 

Chronic fatigue syndrome: what’s in a name?

Comment on: Deeper diagnosis. Multiple determinants of an illness experience. [Can Fam Physician. 1993]

 

I n the article “Deeper Diagnosis,”‘ it is evident that the various physicians involved had gone to great lengths to diagnose the patient’s condition. What is also apparent is the tendency of traditional medicine to “psychologize” any medical presentation that baffles physicians.

Chronic fatigue syndrome was considered during one of the emergency room visits that the patient made. This patient has postviral fatigue syndrome (as researchers in Glasgow, Scotland, call it), chronic fatigue syndrome (as Americans call it), chronic fatigue immune dysfunction syndrome (as patients in North America call it), and benign myalgic encephalomyelitis (as the English and sometimes Canadians call it). Fatigue does not have to be the predominant symptom of postviral fatigue syndrome, and the symptoms can include those of the patient in the article and much more.

You can read the rest of this article, along with the authors’ reply, here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2380224/pdf/canfamphys00100-0022a.pdf

 

Source: Trevor A. Chronic fatigue syndrome: what’s in a name? Can Fam Physician. 1994 Jun;40:1088-9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2380224/

 

The treatment of chronic fatigue syndrome: science and speculation

Abstract:

The chronic fatigue syndrome (CFS) is a heterogeneous disorder characterized by fatigue, neuropsychiatric symptoms, and various other somatic complaints. Treatment studies to date reflect both the diversity of medical disciplines involved in the management of patients with CFS and the multiple pathophysiologic mechanisms proposed.

There have been few attempts to study integrated treatment programs, and although several controlled studies have been reported, no treatment has been shown clearly to result in long-term benefit in the majority of patients. Good clinical care integrating medical and psychologic concepts, together with symptomatic management, may prevent significant secondary impairment in the majority of patients.

Future treatment studies should examine differential response rates for possible subtypes of the disorder (eg, documented viral onset, concurrent clinical depression), evaluate the extent of any synergistic effects between therapies (ie, medical and psychologic), and employ a wide range of biologic and psychologic parameters as markers of treatment response.

 

Source: Wilson A, Hickie I, Lloyd A, Wakefield D. The treatment of chronic fatigue syndrome: science and speculation. Am J Med. 1994 Jun;96(6):544-50. http://www.ncbi.nlm.nih.gov/pubmed/8017453

 

Effort syndrome: hyperventilation and reduction of anaerobic threshold

Abstract:

Effort syndrome is an entity in danger of being subsumed into “chronic fatigue syndrome” and lost to sight. Its distinctive feature is the reduction of the anaerobic threshold for work by depletion of the body’s alkaline buffering systems through hyperventilation. This article describes the history and clinical features of effort syndrome and reports a study in which capnography is used to identify the anaerobic threshold by registering the respiratory response to the onset of metabolic acidosis. The patients’ thresholds are low, and provide a goal for rehabilitation. In other forms of chronic fatigue syndrome, the pathogenesis and logic of therapy are unclear.

 

Source: Nixon PG. Effort syndrome: hyperventilation and reduction of anaerobic threshold. Biofeedback Self Regul. 1994 Jun;19(2):155-69. http://www.ncbi.nlm.nih.gov/pubmed/7918753

 

Chronic fatigue syndrome. ME Association is honest about prognosis

Comment on: Chronic fatigue syndrome: prevalence and outcome. [BMJ. 1994]

 

Editor,-I wish to challenge the assertion by S M Lawrie and A J Pelosi that the prognosis given by some myalgic encephalomyelitis associations is nihilistic. In fact, the figures currently used by the ME Association are in line with the data on chronicity and disability found in various follow up studies of patients, including those of the epidemics of the ’30s, ’40s, and ’50s.

The chronicity of myalgic encephalomyelitis was documented as long ago as 1956 when Sigurdsson and Gudmundsson reported that, of 39 patients involved in the 1948 Icelandic epidemic, only five (1/3%) had recovered completely. Thirty two years later a re-examination of 10 Icelandic patients by Hyde and Bergmann showed that the recovery rate was no more than 20% (two of the 10).

You can read the rest of this comment here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2540204/pdf/bmj00440-0055d.pdf

 

Source: Howes S. Chronic fatigue syndrome. ME Association is honest about prognosis. BMJ. 1994 May 14;308(6939):1299-300. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2540204/

 

Chronic fatigue syndrome. Prevalence study overlooked

Comment on: Chronic fatigue syndrome: prevalence and outcome. [BMJ. 1994]

 

Editor,-It is sad that, in an issue in which Tony Delamothe considers biased reporting of the chronic fatigue syndrome, S M Lawrie and A J Pelosi’s editorial on the subject should be so one sided. The editorial’s title mentions the prevalence of the chronic fatigue syndrome, but the editorial fails to mention the most complete British study. In this study all general practices in two health boards were circulated with a questionnaire. There was a 91% response rate, with most respondents (71%) accepting the existence of the chronic fatigue syndrome when a strict definition was used. The doctors reported a prevalence among their patients of 1-3/1000 patients (range 0-3-2/1000 for the 10 areas surveyed). The higher prevalences were found in more populated areas.

You can read the rest of this comment here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2540208/pdf/bmj00440-0055a.pdf

 

Source: Ho-Yen DO, Shanks M. Chronic fatigue syndrome. Prevalence study overlooked. BMJ. 1994 May 14;308(6939):1299. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2540208/

 

Chronic fatigue syndrome. Immunological findings vary between populations

Comment on: Longitudinal study of outcome of chronic fatigue syndrome. [BMJ. 1994]

 

Editor,-We were interested in Andrew Wilson and colleagues’ paper investigating predictors of the long term outcome of the chronic fatigue syndrome in patients in Australia. We have investigated the association between immune activation and presumed cutaneous anergy in 68 Scottish patients with the syndrome (19 cases conformed to the Centers for Disease Control’s criteria, 18 cases had been diagnosed by a consultant, 28 cases had been diagnosed by a general practitioner, and three patients referred themselves) and 22 family contacts. We assessed delayed hypersensitivity responses (using Multitest antigens and tuberculin skin tests) and evaluated peripheral blood activation markers (CD8, CD38/ CD llb/HLA-DR) using flow cytometry. Patients were classified into three groups on the basis of current severity of illness and mobility.

You can read the rest of this comment here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2540184/pdf/bmj00440-0055b.pdf

 

Source: Abbot NC, Spence VA, Lowe JG, Potts RC, Hassan AH, Belch JJ, Beck JS. Chronic fatigue syndrome. Immunological findings vary between populations. BMJ. 1994 May 14;308(6939):1299. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2540184/